trial

A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.

NCTId NCT04369391
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 150 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2020-11-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
150 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2020-06-18
Primary completion
2020-11-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Ulotarontmoxifloxacin 400 mg

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

7 total
Little Rock, United StatesLong Beach, United StatesPico Rivera, United StatesSan Diego, United StatesHollywood, United StatesMarlton, United StatesAustin, United States

Facts & assertions

4 sourced
Enrollment
150
Phase
PHASE1
Primary Completion Date
2020-11-10
Status
COMPLETED
relationships
The graph out of here
drug
Ulotaront
drug
moxifloxacin 400 mg
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication